Pharmacyclics LLC
- Country
- πΊπΈUnited States
- Ownership
- Subsidiary
- Established
- 1991-01-01
- Employees
- 607
- Market Cap
- -
- Website
- http://www.pharmacyclics.com
A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion
- Conditions
- Chronic Lymphocytic Leukemia With 17p DeletionSmall Lymphocytic Lymphoma With 17p Deletion
- Interventions
- First Posted Date
- 2012-12-07
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 145
- Registration Number
- NCT01744691
Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2012-11-09
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 232
- Registration Number
- NCT01724346
- Locations
- πͺπΈ
Hospital Universitario HM Sanchinarro /ID# 1116-0537, Madrid, Spain
πͺπΈHospital Santa Creu i Sant Pau /ID# 1116-0535, Barcelona, Spain
πΉπ·Gazi Universitesi Tip Fakultes /ID# 1116-0608, Yenimahalle, Ankara, Turkey
Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2012-11-06
- Last Posted Date
- 2017-11-30
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 269
- Registration Number
- NCT01722487
- Locations
- πΊπΈ
Site Reference ID/Investigator #125, Atlanta, Georgia, United States
πΊπΈSite Reference ID/Investigator #050, Pittsburgh, Pennsylvania, United States
πΊπΈSite Reference ID/Investigator #032, Houston, Texas, United States
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
- Conditions
- Relapsed or Refractory Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2012-04-17
- Last Posted Date
- 2019-12-18
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 391
- Registration Number
- NCT01578707
- Locations
- πΊπΈ
Site # 059, New Brunswick, New Jersey, United States
π¦πΊSite # 501, Fitzroy, Victoria, Australia
πΊπΈSite #408, La Jolla, California, United States
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
- First Posted Date
- 2011-11-23
- Last Posted Date
- 2020-03-10
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 92
- Registration Number
- NCT01478581
- Locations
- πΊπΈ
SITE-5, Baltimore, Maryland, United States
πΊπΈSITE-4, Boston, Massachusetts, United States
πΊπΈSITE-13, La Jolla, California, United States
Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
- First Posted Date
- 2011-03-30
- Last Posted Date
- 2017-03-31
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 78
- Registration Number
- NCT01325701
- Locations
- πΊπΈ
UCLA Medical Center, Los Angeles, California, United States
πΊπΈThe Ohio Sate university, Columbus, Ohio, United States
πΊπΈUniverity of Washington, Seattle, Washington, United States
Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Small Lymphocytic LymphomaB-cell Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2011-02-09
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 33
- Registration Number
- NCT01292135
- Locations
- πΊπΈ
Weill Medical College of Cornell University, New York, New York, United States
πΊπΈMD Anderson, Houston, Texas, United States
πΊπΈDana Farber Cancer Center, Boston, Massachusetts, United States
Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
- First Posted Date
- 2010-11-08
- Last Posted Date
- 2015-08-28
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 115
- Registration Number
- NCT01236391
- Locations
- πΊπΈ
New York Presbyterian Hospital/Cornell Medical Center, New York, New York, United States
πΊπΈCll Research and Treatment Program, New Hyde Park, New York, United States
πΊπΈStanford University School of Medicine, Stanford, California, United States
Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL
- Conditions
- B-cell Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaProlymphocyctic LeukemiaRichter's Transformation
- Interventions
- First Posted Date
- 2010-10-08
- Last Posted Date
- 2015-06-25
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 71
- Registration Number
- NCT01217749
- Locations
- πΊπΈ
The Ohio State University, Columbus, Ohio, United States
A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer
- Conditions
- LymphomaNon-Hodgkin's LymphomaHodgkin DiseaseMultiple MyelomaLeukemiaLymphocytic
- Interventions
- First Posted Date
- 2010-06-23
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 7
- Registration Number
- NCT01149668
- Locations
- πΊπΈ
Northwestern Univ. Med School, Chicago, Illinois, United States
πΊπΈNebraska Methodist Hospital, Omaha, Nebraska, United States
πΊπΈUniv. of Nebraska Medical Center, Omaha, Nebraska, United States